Asset
TTI-101
Tvardi Therapeutics Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05440708 | phase1_2 | recruiting | 2023-03-23 | 2027-02-01 | Tvardi Therapeutics, Incorporated | A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma |
| NCT03195699 | phase1 | completed | 2017-11-15 | 2024-06-24 | Tvardi Therapeutics, Incorporated | Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers |
| NCT05384119 | phase1 | terminated | 2023-01-09 | 2024-04-25 | Tvardi Therapeutics, Incorporated | Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer |
| NCT05671835 | phase2 | completed | 2023-05-15 | 2025-08-14 | Tvardi Therapeutics, Incorporated | Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis |
FDA applications (0)
This company has no applications containing this asset.